GUEST EDITORIAL

2016 National Rheumatic Fever Week: The status of rheumatic heart disease in South Africa

Over 25 years ago, the National Department of Health (NDoH) declared the first week of August National Rheumatic Fever Week following the efforts of John Barlow, Budgie van der Merwe and others to focus the attention of the nation on the need to implement proven interventions to reduce the incidence of acute rheumatic fever (ARF) and the prevalence of rheumatic heart disease (RHD).[3,4] It was at this time that ARF was made a notifiable condition, although the uptake of notification was subsequently found to be suboptimal.[3] In October 2005, the NDoH hosted the 1st Pan-African Workshop on Acute Rheumatic Fever and Rheumatic Heart Disease, together with the World Health Organization (Africa Region), the World Heart Federation, the Pan-African Society of Cardiology and the South African Heart and Stroke Foundation, where the Drakensberg Declaration was adopted.[4] The Drakensberg conference issued a clarion call to African governments and their ministries of health to initiate national programmes to eliminate ARF and control RHD by raising awareness among the public and professionals, measurement of the burden of disease through surveillance studies, improvement of medical and surgical care through advocacy, and the widespread use of penicillin in primary and secondary prevention activities (the A.S.A.P. Programme).[3]

A.S.A.P. has inspired new research that has provided vital information on the status of ARF and RHD in Africa and the world.[9] South African (SA) studies reveal a changing pattern of disease at hospital and population levels. Hospital-based studies show a high incidence of congestive heart failure caused by RHD (average of 25 cases/100 000/year in Soweto) that is associated with high 60-day and 180-day mortality rates of 24.8% (95% confidence interval (CI) 13.6 - 42.5) and 35.4% (95% CI 21.6 - 54.4), respectively.[7,8] This high incidence of congestive heart failure caused by RHD (average of 25 cases/100 000/year in Soweto) that is associated with high 60-day and 180-day mortality rates of 24.8% (95% confidence interval (CI) 13.6 - 42.5) and 35.4% (95% CI 21.6 - 54.4), respectively.[7,8] This high burden of heart failure and mortality in adults has to be contrasted with a falling caseload of ARF and RHD in children, as demonstrated in Soweto recently (Fig. 1). Furthermore, there has been a fall in cause-specific mortality from RHD over the past 15 years (Fig. 2). These changes are consistent with a transition of ARF/RHD from a condition of childhood to a mature endemic disease of adults. The changes may reflect a ‘Mandela dividend’ associated with the improvement in access to primary healthcare and rising socioeconomic status of South Africans since the advent of the new SA in 1994.[10]

The ‘In Practice’ article in this issue of SAMJ on the role of screening echocardiography for RHD in the school health programme by Shung-King et al.[10] and the letter describing a regimen for the painless administration of intramuscular penicillin by Madeira et al.[11] address important issues in the quest to end RHD. The commentary by Shung-King et al.[10] is a response to an echocardiographic screening study of schoolchildren in Cape Town that showed a prevalence of latent RHD of 20 - 30 per 1 000 among asymptomatic schoolchildren, although about 50% of these cases revert to normal after 5 years of follow-up.[12,13] Screening echocardiography is not recommended as a routine test in the school health programme until studies of its impact on prognosis and cost-effectiveness are conducted.[10,14] The advice by Madeira et al.[11] on the use of lignocaine as a diluent for benzathine penicillin is relevant not only to practitioners who use injectable penicillin on a regular basis for the primary and secondary prevention of ARF, but also to those whose patients need penicillin prophylaxis against recurrent infections in sickle cell disease and immune deficiencies.[15,16]

There has been significant progress in the uptake of the A.S.A.P. call by African governments. In June 2015, the heads of state of African countries endorsed the Addis Ababa Communiqué, which sets out seven actions for addressing the barriers to RHD control that were identified in the REMEDY study.[12,13] These as follows: (i) creation of prospective disease registers at sentinel sites in affected countries to measure disease burden and track progress towards the reduction of mortality by 25% by the year 2025, as mandated by the World Health Organization;[12] (ii) provision of an adequate supply of high-quality benzathine penicillin for primary and secondary prevention; (iii) improvement of access to reproductive health services for women with RHD and other non-communicable diseases (NCDs); (iv) decentralisation of technical expertise and technology for diagnosing and managing ARF and RHD (including ultrasound of the heart); (v) establishment of national and regional centres of...
excellence for essential cardiac surgery for the treatment of affected patients and the training of cardiovascular practitioners of the future; (vii) initiation of national multisectoral RHD programmes within NCD control programmes of affected countries; and (vii) fostering of international partnerships with multinational organisations for resource mobilisation, monitoring and evaluation of the programme to end RHD in Africa.[18]

SA has the conditions that are required for success in eradicating ARF and ending RHD. The NDoH has prioritised the prevention of the disease through initiatives such as National Rheumatic Fever Week, the inclusion of ARF among notifiable conditions, and efforts to improve access to primary healthcare. Health practitioners need to play their role by notifying cases of ARF, treating all children with a sore throat with penicillin according to the SA guidelines,[20] and entering all our patients with RHD in the electronic register.[21] These measures, together with other actions outlined in the Addis Ababa Communiqué, if implemented across the health system, will hasten the demise of ARF and bring RHD under control by the year 2025.

Bongani M Mayosi
Department of Medicine, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, South Africa
bongani.mayosi@uct.ac.za


